Skip to main content

Urinary Urge Incontinence

0
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Neuspera Medical
Neuspera MedicalCA - San Jose
2 programs
Neuspera Implantable Sacral Neuromodulation SystemN/A1 trial
Neuspera Implantable Sacral Neuromodulation SystemN/A1 trial
Active Trials
NCT07247136Recruiting30Est. Nov 2026
NCT07383688Not Yet Recruiting100Est. Oct 2026
Axonics
AxonicsCA - Irvine
1 program
Axonics External Trial SystemN/A1 trial
Active Trials
NCT07335484Not Yet Recruiting75Est. Dec 2026
BlueWind Medical
BlueWind MedicalIsrael - Herzliya
1 program
Revi System TreatmentN/A1 trial
Active Trials
NCT06217328Active Not Recruiting150Est. Feb 2027

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
AxonicsAxonics External Trial System
Neuspera MedicalNeuspera Implantable Sacral Neuromodulation System
Neuspera MedicalNeuspera Implantable Sacral Neuromodulation System
BlueWind MedicalRevi System Treatment

Clinical Trials (4)

Total enrollment: 355 patients across 4 trials

NCT07335484AxonicsAxonics External Trial System

Aquarius Pilot Study to Evaluate the New Axonics Trial System

Start: Apr 2026Est. completion: Dec 202675 patients
N/ANot Yet Recruiting
NCT07383688Neuspera MedicalNeuspera Implantable Sacral Neuromodulation System

FREEDOM Registry - Follow up Revision Experience and Evaluation of Device Outcomes Metrics

Start: Mar 2026Est. completion: Oct 2026100 patients
N/ANot Yet Recruiting
NCT07247136Neuspera MedicalNeuspera Implantable Sacral Neuromodulation System

Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System

Start: Nov 2025Est. completion: Nov 202630 patients
N/ARecruiting
NCT06217328BlueWind MedicalRevi System Treatment

RESTORE: An RCT to Evaluate the Efficacy of the Revi System

Start: Feb 2024Est. completion: Feb 2027150 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 355 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.